Back to results
US 2006/0069161 A1Published application
Methods and reagents for the treatment of metabolic disorders
AssigneeCombinatoRx, Incorporated
InventorsMargaret Lee, Grant Zimmermann, Alyce Finelli, Daniel Grau, Curtis Keith, M. Nichols
Life of this patent
Estimating the term…
Abstract
The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.
Claims97
A composition comprising:
- (a) bezafibrate or an analog thereof;
- and
- (b) diflunisal, cinnamic acid, or an analog thereof, wherein said bezafibrate and diflunisal or cinnamic acid are present in amounts that, when administered to a patient, are sufficient to treat, prevent, or reduce a metabolic disorder.
A method for treating, preventing, or reducing a metabolic disorder in a patient in need thereof, said method comprising administering to said patient
- (i) bezafibrate or an analog thereof;
- and
- (ii) diflunisal, cinnamic acid, or an analog thereof,
- wherein said bezafibrate and diflunisal are administered in amounts that together are sufficient to treat, prevent, or reduce a metabolic disorder.
1 more element
A kit comprising:
- (i) bezafibrate or an analog thereof;
- and
- (ii) instructions for administering said bezafibrate and cinnamic acid or an analog thereof to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) bezafibrate or an analog thereof;
- and
- (ii) instructions for administering said bezafibrate and diflunisal or an analog thereof to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) diflunisal or an analog thereof;
- and
- (ii) instructions for administering said diflunisal and bezafibrate or an analog thereof to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) cinnamic acid or an analog thereof;
- and
- (ii) instructions for administering said cinnamic acid and bezafibrate or an analog thereof to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) a composition comprising bezafibrate or an analog thereof and cinnamic acid or an analog thereof;
- and
- (ii) instructions for administering said composition to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) a composition comprising bezafibrate or an analog thereof and diflunisal or an analog thereof;
- and
- (ii) instructions for administering said composition to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) bezafibrate or an analog thereof;
- (ii) cinnamic acid or an analog thereof;
- and
- (iii) instructions for administering said bezafibrate and said cinnamic acid to a patient having or at risk of having a metabolic disorder.
1 more element
A kit comprising:
- (i) bezafibrate or an analog thereof;
- (ii) diflunisal or an analog thereof;
- and
- (iii) instructions for administering said bezafibrate and said diflunisal to a patient having or at risk of having a metabolic disorder.
1 more element
A composition comprising:
- (a) a PPAR agonist;
- and
- (b) diflunisal, cinnamic acid, or an analog thereof, wherein said PPAR agonist and diflunisal or cinnamic acid are present in amounts that, when administered to a patient, are sufficient to treat, prevent, or reduce a metabolic disorder.
A method for treating, preventing, or reducing a metabolic disorder in a patient in need thereof, said method comprising administering to said patient
- (i) a PPAR agonist;
- and
- (ii) diflunisal, cinnamic acid, or an analog thereof,
- wherein said PPARγ agonist and diflunisal or cinnamic acid are administered in amounts that together are sufficient to treat, prevent, or reduce a metabolic disorder.
1 more element
A kit comprising:
- (i) a PPAR agonist;
- and
- (ii) instructions for administering said PPAR agonist and cinnamic acid or an analog thereof to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) a PPAR agonist;
- and
- (ii) instructions for administering said PPAR agonist and diflunisal or an analog thereof to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) diflunisal or an analog thereof;
- and
- (ii) instructions for administering said diflunisal and a PPAR agonist or an analog thereof to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) cinnamic acid or an analog thereof;
- and
- (ii) instructions for administering said cinnamic acid and a PPAR agonist or an analog thereof to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) a composition comprising a PPAR agonist or an analog thereof and cinnamic acid or an analog thereof;
- and
- (ii) instructions for administering said composition to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) a composition comprising a PPAR agonist or an analog thereof and diflunisal or an analog thereof;
- and
- (ii) instructions for administering said composition to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) a PPAR agonist or an analog thereof;
- (ii) cinnamic acid or an analog thereof;
- and
- (iii) instructions for administering said PPAR agonist and said cinnamic acid to a patient having or at risk of having a metabolic disorder.
1 more element
A kit comprising:
- (i) a PPAR agonist or an analog thereof;
- (ii) diflunisal or an analog thereof;
- and
- (iii) instructions for administering said PPAR agonist and said diflunisal to a patient having or at risk of having a metabolic disorder.
1 more element
A composition comprising:
- (a) a first agent selected from any one of the agents of Table 1;
- and
- (b) a second agent, wherein said second agent is selected from the group consisting of a sulfonylurea, non-sulfonylurea secretagogue, insulin, insulin analog, glucagon-like peptide, exendin-4, YM178, FK614, dipeptidyl peptidase IV inhibitor, biguanide, thiazalidinedione, alpha-glucosidase inhibitor, immunosuppressant, immunomodulator, angiotensin converting enzyme (ACE) inhibitor, angiotensin II receptor blocker, and antioxidant;
- wherein said first agent and said second agent are present in amounts that, when administered to a mammal, are sufficient to treat, prevent, or reduce a metabolic disorder.
1 more element
A method for treating, preventing, or reducing a metabolic disorder, said method comprising administering to a mammal one or more agents selected from any one of the agents of Table 1 in an amount sufficient to treat, prevent, or reduce said metabolic disorder.
A method for treating, preventing, or reducing a metabolic disorder, said method comprising administering to a mammal at least two different agents from Table 1, wherein the first and second agents are administered simultaneously or within 28 days of each other, in amounts that together are sufficient to treat, prevent, or reduce said metabolic disorder.
A kit comprising:
- (i) an agent selected from any one of the agents of Table 1;
- and
- (ii) instructions for administering said agent to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) a composition comprising two agents selected from any one of the agents of Table 1;
- and
- (ii) instructions for administering said composition to a patient having or at risk of having a metabolic disorder.
A kit comprising:
- (i) a first agent selected from any one of the agents of Table 1;
- (ii) a second agent selected from any one of the agents of Table 1;
- and
- (iii) instructions for administering said first and said second agents to a patient having or at risk of having a metabolic disorder.
1 more element
A kit comprising:
- (i) an agent selected from any one of the agents of Table 1;
- and
- (ii) instructions for administering said agent with a second agent selected from any one of the agents of Table 1 to a patient having or at risk of having a metabolic disorder, wherein said second agent is not the agent in (i).
A kit, comprising:
- (i) a composition comprising
- (a) a first agent selected from any one of the agents of Table 1;
- and
- (b) a second agent selected from the group consisting of a sulfonylurea, non-sulfonylurea secretagogue, insulin, insulin analog, glucagon-like peptide, exendin-4, YM178, FK614, dipeptidyl peptidase IV inhibitor, biguanide, thiazalidinedione, alphaglucosidase inhibitor, immunosuppressant, immunomodulator, angiotensin converting enzyme (ACE) inhibitor, angiotensin II receptor blocker, and antioxidant;
- and
- (ii) instructions for administering said composition to a patient having or at risk of having a metabolic disorder.
3 more elements
A kit, comprising:
- (i) a first agent selected from any one of the agents of Table 1;
- and
- (ii) a second agent selected from the group consisting of a sulfonylurea, non-sulfonylurea secretagogue, insulin, insulin analog, glucagon-like peptide, exendin-4, YM178, FK614, dipeptidyl peptidase IV inhibitor, biguanide, thiazalidinedione, alphaglucosidase inhibitor, immunosuppressant, immunomodulator, angiotensin converting enzyme (ACE) inhibitor, angiotensin II receptor blocker, and antioxidant;
- and
- (iii) instructions for administering said first and said second agents to a patient having or at risk of having a metabolic disorder.
2 more elements
A kit comprising:
- (i) an agent selected from any one of the agents of Table 1;
- and
- (ii) instructions for administering said agent and a second agent to a patient having or at risk of having a metabolic disorder, wherein said second agent is selected from the group consisting of a sulfonylurea, non-sulfonylurea secretagogue, insulin, insulin analog, glucagon-like peptide, exendin-4, YM178, FK614, dipeptidyl peptidase IV inhibitor, biguanide, thiazalidinedione, alpha-glucosidase inhibitor, immunosuppressant, immunomodulator, angiotensin converting enzyme (ACE) inhibitor, angiotensin II receptor blocker, and antioxidant.
A kit comprising:
- (i) an agent selected from the group consisting of a sulfonylurea, non-sulfonylurea secretagogue, insulin, insulin analog, glucagon-like peptide, exendin-4, YM178, FK614, dipeptidyl peptidase IV inhibitor, biguanide, thiazalidinedione, alpha-glucosidase inhibitor, immunosuppressant, immunomodulator, angiotensin converting enzyme (ACE) inhibitor, angiotensin II receptor blocker, and antioxidant;
- and
- (ii) instructions for administering said agent from (i) with any agent selected from any one of the agents of Table 1 to a patient having or at risk of having a metabolic disorder.
A method of identifying a combination that may be useful for the treatment, prevention, or reduction of a metabolic disorder, said method comprising the steps of:
- (a) contacting cells with an agent selected from any one the agents of Table 1 and a candidate compound;
- and
- (b) determining whether the combination of said agent and said candidate compound reduces glucose levels relative to cells contacted with said agent but not contacted with the candidate compound, wherein a reduction in glucose levels identifies the combination as a combination useful for the treatment, prevention, or reduction of a metabolic disorder.
A method of identifying a combination that may be useful for the treatment, reduction, or prevention of a metabolic disorder, said method comprising the steps of:
- (a) contacting cells with an agent selected from any one of the agents of Table 1 and a candidate compound;
- and
- (b) determining whether the combination of said agent and said candidate compound alter insulin signaling such that glucose levels are reduced relative to cells contacted with said agent but not contacted with said candidate compound, wherein an alteration resulting in an increase in glucose reduction identifies the combination as a combination useful for the treatment, prevention, or reduction of a metabolic disorder.
Dependencies are inferred from the claim text.